Lilly's Obesity Pill Gains Traction as Chip Stocks Attempt a Rebound

A Bank of America physician survey suggests Lilly's oral obesity drug is expanding the GLP-1 market rather than merely shifting existing patients, while a fragile semiconductor rebound shows risk appetite remains unsettled.
Monday's market rebound carried two different signals for investors. Semiconductor shares tried to end a bruising stretch, while fresh physician data strengthened the case that Eli Lilly's oral obesity treatment can enlarge the GLP-1 market.
The iShares Semiconductor ETF was on course to break a nine-session losing streak, its worst run since May 2006. Yet the recovery was unconvincing: the fund faded from its intraday high, and CoreWeave turned lower and set a new 2026 low below $60. The Nasdaq gained about 1%, but defensive health-care and consumer-staples shares gave back some of the prior week's gains as money rotated back toward chips.
Oil added another macro complication. West Texas Intermediate rose roughly $2 to around $103 a barrel, reviving inflation concerns and pushing Treasury yields higher as bond prices fell. That combination matters because expensive energy and higher yields can make richly valued technology shares harder to support.
Lilly's news was more company-specific. Bank of America raised its price target to $1,397 from $1,341 after a third-quarter physician survey found that about 70% of oral GLP-1 and Medicare Bridge volumes came from patients who were new to treatment or restarting it. That supports Lilly's argument that pills and broader reimbursement are adding patients rather than simply moving people away from injections.
Lilly launched Foundayo in April, about three months after Novo Nordisk introduced an oral version of Wegovy, and Medicare coverage began July 1. The survey put Foundayo at 27% of new oral GLP-1 starts and indicated physicians expect a 40% share by 2028 or 2029.
The next hard test is Lilly's Oct. 29 earnings report. Investors will need prescription trends and management commentary to show whether survey intentions are turning into durable demand, especially as Novo's pill remains a credible competitor despite food-and-water restrictions.
Continue your NVO research
Related News
TJX Rebound Prompts a Hold Call as AI Stocks Extend Their Slide
A CNBC Investing Club update downgraded TJX to hold after a rebound pushed the position above 4% of its portfolio. The same session showed investors rotating away from capital-intensive AI stocks into defensives.
Trump Media and Rumble Fell Faster Than the Market as Merger Risk Loomed
Trump Media dropped 6% and Rumble 8% during a broader selloff, highlighting their high volatility. For DJT, the pending TAE merger adds execution, dilution and fusion-development risk.
Carnival's Record 2027 Bookings Shift Attention to Pricing
Carnival reported record booked occupancy and pricing for 2027, supporting demand visibility after a strong share-price rebound. The next test is whether realized yields and costs preserve that advantage.
CoreWeave Credit Insurance Tops 1,000 Basis Points as Debt Fears Rise
CoreWeave's five-year credit-default swaps moved above 1,000 basis points while a 2031 bond yielded about 14.5%. Those market prices signal severe perceived credit risk even though the company continues to add long-term customer commitments.
Reddit's 61% Growth Supports Its Premium, but the Next Quarter Slows
Reddit's second-quarter revenue rose 61% and weekly active uniques reached 514.6 million, supporting a richer valuation than slower-growing peers. Management's third-quarter guide, however, implies a clear deceleration and leaves search traffic as a risk.
Disc Medicine's Phase 3 Win Clears the Clinical Bar, Not the FDA Bar
Bitopertin met both primary endpoints in Disc Medicine's pivotal APOLLO trial, strengthening its planned response to an earlier FDA rejection. The next value-driving step is regulatory acceptance, not another share-price reaction.













Latest comments